Results 71 to 80 of about 5,288 (183)
eJHaemIntroduction Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long‐term side effects.
Benjamin Heyman +2 more
doaj +1 more source
Blood and Lymphatic Cancer: Targets and Therapy, 2022 Frédérique St-Pierre,1 Shuo Ma1,2 1Department of Medicine, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA; 2Department of Medicine, Division of Hematology/Oncology, Feinberg ...
St-Pierre F, Ma S
doaj
Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders
International Journal of Laboratory Hematology, EarlyView.ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley +1 more source
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. [PDF]
, 2016 Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that
Chen, L +9 more
core +1 more source
Therapeutic advances in pruritus as a model of personalized medicine
Journal of the European Academy of Dermatology and Venereology, EarlyView.Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung +2 more
wiley +1 more source
American Journal of Ophthalmology Case ReportsPurpose: To report two new cases and summarize one case of uveal melanoma following treatment of hematologic malignancies with Bruton's tyrosine kinase inhibitors.
Tara Murty +2 more
doaj +1 more source
Frontiers in Cell and Developmental Biology, 2020 Overexpression of ATP-binding cassette subfamily B member 1 (ABCB1) remains one of the most vital factors leading to multidrug resistance (MDR). It is important to enhance the effect and bioavailability of chemotherapeutic drugs that are substrates of ...
Xing-Duo Dong +11 more
doaj +1 more source
eJHaem, 2023 Patients with Waldenström macroglobulinaemia (WM) are at increased risk of severe COVID‐19 infection and have poor immune responses to COVID‐19 vaccination. This study assessed whether a closely monitored pause in Bruton's Tyrosine Kinase inhibitor (BTKi)
Katherine Rankin +10 more
doaj +1 more source
Polo‐like kinases and UV‐induced skin carcinogenesis: What we know and what's next
Photochemistry and Photobiology, EarlyView.The polo‐like kinase (PLK) family plays distinct and critical roles in the regulation of cell cycle progression, and its dysregulation has been implicated in various cancers. Ultraviolet (UV) radiation is a well‐established environmental factor in the development of skin cancer.
Tanya Jaiswal +3 more
wiley +1 more source
International Journal of Cancer, Volume 158, Issue 7, Page 1836-1845, 1 April 2026.What's new? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg +5 more
wiley +1 more source